REGENERON PHARMACEUTICALS, INC.
REGN · SEC filer number (CIK) 0000872589 · figures from FY2025
The last reported year
Revenue
$14.3B
+1.0% on the year before
Operating margin
24.9%
Net income
$4.5B
Return on invested capital
9.6%
Operating profit after tax
Read from this company's 10-K, filed 2026-02-04. See the filing on EDGAR
Six years
| Year | Revenue | Operating income | Net income |
|---|---|---|---|
| FY2025 | $14.3B | $3.6B | $4.5B |
| FY2024 | $14.2B | $4.0B | $4.4B |
| FY2023 | $13.1B | $4.0B | $4.0B |
| FY2022 | $12.2B | $4.7B | $4.3B |
| FY2021 | $16.1B | $8.9B | $8.1B |
| FY2020 | $8.5B | $3.6B | $3.5B |
Each year is shown as the company first reported it. 2 figures above were later republished by this company with a different number; the full research page shows both.
The rest of the research
Materiality reads REGN's filings in full: every statement line with the concept it was tagged under, the ratios above across twenty years, cash flow, segment and dividend history, insider and institutional ownership, and a written analysis built only from the figures on the page.
Open the full research